Milestones of Lynch syndrome: 1895-2015

Nature Reviews Cancer

Volumn 15, Issue 3, 2015, Pages 181-194

  Lynch, Henry T ^a   Snyder, Carrie L ^a   Shaw, Trudy G ^a   Heinen, Christopher D ^b   Hitchins, Megan P ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MISMATCH REPAIR; MOLECULAR GENETICS; PRIORITY JOURNAL; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETICS; HISTORY;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY;

EID: 84923585166     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3878     Document Type: Article

References (202)

1. Warthin, A. S. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch. Intern. Med. 12, 546-555 (1913). This is the first published paper describing what has become known as LS.
2. Mendel, G. Versuche über Pflanzen-Hybriden. Verh. Naturforsch. Ver. Brünn 4, 3-47 (1866); English translation available in J. R. Hortic. Soc. 26, 1-32 (1901).
3. Desai, D. C. et al. Recurrent germline mutation in MSH2 arises frequently de novo. J. Med. Genet. 37, 646-652 (2000).
4. Lynch, H. T., Shaw, M. W., Magnuson, C. W., Larsen, A. L. & Krush, A. J. Hereditary factors in cancer: study of two large Midwestern kindreds. Arch. Intern. Med. 117, 206-212 (1966). This paper reopened interest in LS, which had been dormant since the work of Warthin.
5. Lynch, H. T. & Krush, A. J. Cancer family "G" revisited: 1895-1970. Cancer 27, 1505-1511 (1971).
6. Douglas, J. A. et al. History and molecular genetics of Lynch syndrome in Family G: a century later. JAMA 294, 2195-2202 (2005).
7. Lynch, H. T. & Krush, A. J. The cancer family syndrome and cancer control. Surg. Gynecol. Obstet. 132, 247-250 (1971). This report details early cancer diagnosis through increased surveillance in CFS.
8. Boland, C. R. & Troncale, F. J. Familial colonic cancer without antecedent polyposis. Ann. Intern. Med. 100, 700-701 (1984). This was the first paper to suggest the term LS for CFS.
9. Tempero, M. A., Jacobs, M. M., Lynch, H. T., Graham, C. L. & Blotcky, A. J. Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer. Biol. Trace Element Res. 6, 51-55 (1984).
10. Kalady, M. F., Kravochuck, S., LaGuardia, L., O'Malley, M. & Church, J. M. Adenomas in Lynch syndrome: don't be fooled by the "non" in hereditary nonpolyposis colorectal cancer. Fam Cancer 12 (Suppl. 2), 53 (2013). This is a recent study demonstrating an excess of adenomas in LS.
11. Boland, C. R. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam. Cancer 4, 211-218 (2005). In the context of the developing nomenclature for LS, this paper gives a succinct summary of the history of hereditary CRC until that time.
12. Jass, J. R. Hereditary non-polyposis colorectal cancer: The rise and fall of a confusing term. World J. Gastroenterol. 12, 4943-4950 (2006).
13. Lynch, P. M., Lynch, H. T. & Harris, R. E. Hereditary proximal colonic cancer. Dis. Colon Rectum 20, 661-668 (1977). This was the first paper to note the predilection for the proximal colon of LS-associated CRCs.
14. Lanspa, S. J. et al. Surveillance in Lynch syndrome: how aggressive? Am. J. Gastroenterol. 89, 1978-1980 (1994). This paper calls for complete colonoscopy in surveillance for LS-associated CRCs.
15. Rondagh, E. J. A. et al. Nonpolypoid colorectal neoplasms: a challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy 45, 257-264 (2013).
16. Watson, P. & Lynch, H. T. The tumor spectrum in HNPCC. Anticancer Res. 14, 1635-1640 (1994).
17. Watson, P. et al. The risk of extra-colonic, extraendometrial cancer in the Lynch syndrome. Int. J. Cancer 123, 444-449 (2008).
18. Lynch, H. T., Lynch, P. M., Pester, J. & Fusaro, R. M. The cancer family syndrome: rare cutaneous phenotypic linkage of Torre's syndrome. Arch. Intern. Med. 141, 607-611 (1981). This paper was the first to demonstrate that Muir-Torre syndrome is a variant of LS.
19. Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302, 1790-1795 (2009).
20. Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 30, 958-964 (2012).
21. Bauer, C. M. et al. Hereditary prostate cancer as a feature of Lynch syndrome. Fam. Cancer 10, 37-42 (2011).
22. Raymond, V. M. et al. Adrenocortical carcinoma is a Lynch syndrome-associated cancer. J. Clin. Oncol. 31, 3012-3018 (2013).
23. Vasen, H. F. A., Mecklin, J.-P., Meera Khan, P. & Lynch, H. T. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICGHNPCC). Dis. Colon Rectum 34, 424-425 (1991). This paper is the source of the Amsterdam I Criteria for LS.
24. Vasen, H. F. A., Watson, P., Mecklin, J.-P. & Lynch, H. T. & ICG-HNPCC. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116, 1453-1456 (1999). This is the source of the revised Amsterdam II Criteria.
25. Boland, C. R. et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998).
26. Rodriguez-Bigas, M. A. et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J. Natl Cancer Inst. 89, 1758-1762 (1997).
27. Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96, 261-268 (2004). This is the source of the Revised Bethesda Guidelines for MSI testing.
28. Blackwell, L. J., Wang, S. & Modrich, P. DNA chain length dependence of formation and dynamics of hMutSα.hMutLα.heteroduplex complexes. J. Biol. Chem. 276, 33233-33240 (2001).
29. Farabaugh, P. J., Schmeissner, U., Hofer, M. & Miller, J. H. Genetic studies of the lac repressor. VII. On the molecular nature of spontaneous hotspots in the lacl gene of Escherichia coli. J. Mol. Biol. 126, 847-857 (1978).
30. Streisinger, G. & Owen, J. E. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics 109, 633-659 (1985).
31. Levinson, G. & Gutman, G. A. High frequencies of short frameshifts in poly-CA/TG tandem repeats borne by bacteriophage M13 in Escherichia coli K-12. Nucleic Acids Res. 15, 5323-5338 (1987).
32. Modrich, P. Methyl-directed DNA mismatch correction. J. Biol. Chem. 264, 6597-6600 (1989).
33. Strand, M., Prolla, T. A., Liskay, R. M. & Petes, T. D. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 365, 274-276 (1993).
34. Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816 (1993). This was the first study to link MSI with LS.
35. Ionov, Y. M., Peinado, M. A., Malkhosyan, S., Shibata, D. & Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363, 558-561 (1993).
36. Thibodeau, S. N., Bren, G. & Schaid, D. Microsatellite instability in cancer of the proximal colon. Science 260, 816-819 (1993).
37. Parsons, R. et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75, 1227-1236 (1993). This is an early description of hypermutability in MSI.
38. Jass, J. R. Natural history of hereditary non-polyposis colorectal cancer. J. Tumor Marker Oncol. 10, 65-71 (1995).
39. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
40. Jass, J. R. et al. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res. 14, 1631-1634 (1994). This was the first comprehensive listing of pathological features found in LS-associated CRCs.
41. Watson, P. et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal cancer family members. Cancer 83, 259-266 (1998). This study documents the survival advantage of LS-associated CRC compared with sporadic CRC.
42. Deschoolmeester, V. et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 11, 19 (2010).
43. Hamilton, S. R. in Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management Ch. 6 (eds Benson, A. B, Chakravarthy, A., Hamilton, S. R., Sigurdson, E. & Thomas, C. Jr) 115-128 (Demos Medical Publishing, 2014). This book chapter gives an up-to-date understanding of pathological features in CRC.
44. Bartley, A. N. et al. Colorectal adenoma stem-like cell populations: associations with adenoma characteristics and metachronous colorectal neoplasia. Cancer Prev. Res. 6, 1162-1170 (2013).
45. Peltomäki, P. et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 260, 810-812 (1993). This was the first study to show a germline mutation as a cause of LS.
46. Lindblom, A., Tannergard, P., Werelius, B. & Nordenskjold, M. Genetic mapping of a second locus predisposing to hereditary nonpolyposis colorectal cancer. Nature Genet. 5, 279-282 (1993). This study links LS to a second locus.
47. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038 (1993).
48. Leach, F. S. et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75, 1215-1225 (1993). References 47 and 48 document the discovery of the connection between MSH2 and LS.
49. Papadopoulos, N. et al. Mutation of a mutL homolog in hereditary colon cancer. Science 263, 1625-1629 (1994).
50. Bronner, C. E. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 368, 258-261 (1994). References 49 and 50 document the discovery of the connection between MLH1 and LS.
51. Nicolaides, N. C. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371, 75-80 (1994). This study was the first to link the PMS genes to LS.
52. Liu, T. et al. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res. 61, 7798-7802 (2001).
53. Miyaki, M. et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nature Genet. 17, 271-272 (1997). This paper shows the involvement of MSH6 in LS.
54. Lipkin, S. M. et al. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nature Genet. 24, 27-34 (2000). This paper connects MLH3 with MSI.
55. Wu, Y. et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nature Genet. 29, 137-138 (2001).
56. Liu, H. X. et al. The role of hMLH3 in familial colorectal cancer. Cancer Res. 63, 1894-1899 (2003).
57. Korhonen, M. K., Vuorenmaa, E. & Nyström, M. The first functional study of MLH3 mutations found in cancer patients. Genes Chromosomes Cancer 47, 803-809 (2008).
58. Ou, J. et al. Biochemical characterization of MLH3 missense mutations does not reveal an apparent role of MLH3 in Lynch syndrome. Genes Chromosomes Cancer 48, 340-350 (2009).
59. Rasmussen, L. J. et al. Pathological assessment of mismatch repair gene variants in Lynch syndrome. Hum. Mutat. 33, 1617-1625 (2012).
60. Nystrom-Lahti, M. et al. Founding mutations and Alumediated recombination in hereditary colon cancer. Nature Med. 1, 1203-1206 (1995).
61. Marshall, B., Isidro, G. & Boavida, M. G. Insertion of a short Alu sequence into the hMSH2 gene following a double cross over next to sequences with chi homology. Gene 174, 175-179 (1996).
62. Wijnen, J. et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nature Genet. 20, 326-328 (1998). This study shows the use of Southern blotting to identify genomic rearrangements in MSH2.
63. Yan, H. et al. Conversion of diploidy to haploidy: individuals susceptible to multigene disorders may now be spotted more easily. Nature 403, 723-724 (2000).
64. Charbonnier, F. et al. MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res. 62, 848-853 (2002).
65. Gille, J. J. et al. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br. J. Cancer 87, 892-897 (2002).
66. Plazzer, J. P. et al. The insight database: utilizing 100 years of insights into Lynch syndrome. Fam. Cancer 12, 175-180 (2013).
67. Wagner, A. et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am. J. Hum. Genet. 72, 1088-1100 (2003).
68. Lynch, H. T. et al. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 291, 718-724 (2004). This paper describes the discovery of a widespread founder mutation in the United States.
69. Clendenning, M. et al. Long-range PCR facilitates the identification of PMS2-specific mutations. Hum. Mutat. 27, 490-495 (2006).
70. Vaughn, C. P. et al. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Hum. Mutat. 31, 588-593 (2010).
71. Vaughn, C. P., Baker, C. L., Samowitz, W. S. & Swensen, J. J. The frequency of previously undetectable deletions involving 3'exons of the PMS2 gene. Genes Chromosomes Cancer 52, 107-112 (2013).
72. Wimmer, K. & Wernstedt, A. PMS2 gene mutational analysis: direct cDNA sequencing to circumvent pseudogene interference. Methods Mol. Biol. 1167, 289-302 (2014).
73. Pritchard, C. C. et al. ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J. Mol. Diagn. 14, 357-366 (2012).
74. Gazzoli, I., Loda, M., Garber, J., Syngal, S. & Kolodner, R. D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62, 3925-3928 (2002).
75. Hitchins, M. P. The role of epigenetics in Lynch syndrome. Fam. Cancer 12, 189-205 (2013). This is a recent review of the role of epigenetics in LS.
76. Hitchins, M. et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 129, 1392-1399 (2005). This was the first description of MLH1 epimutations in LS.
77. Hitchins, M. et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. Cancer Cell 20, 200-213 (2011). This paper describes a dominantly inherited epimutation in MLH1.
78. Morak, M. et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. J. Med. Genet. 48, 513-519 (2011).
79. Kwok, C. T. et al. The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. Eur. J. Hum. Genet. 22, 617-624 (2014).
80. Chan, T. L. et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nature Genet. 38, 1178-1183 (2006).
81. Ligtenberg, M. J. L. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3? exons of TACSTD1. Nature Genet. 41, 112-117 (2009). This paper describes the effect of EPCAM deletions on MSH2.
82. Zhang, Y. et al. Reconstitution of 5'-directed human mismatch repair in a purified system. Cell 122, 693-705 (2005).
83. Constantin, N., Dzantiev, L., Kadyrov, F. A. & Modrich, P. Human mismatch repair: reconstitution of a nickdirected bidirectional reaction. J. Biol. Chem. 280, 39752-39761 (2005).
84. Hsieh, P. & Yamane, K. DNA mismatch repair: Molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 129, 391-407 (2008).
85. Kunkel, T. A. & Erie, D. A. DNA mismatch repair. Ann. Rev. Biochem. 74, 681-710 (2005).
86. Acharya, S. et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc. Natl Acad. Sci. USA 93, 13629-13634 (1996).
87. de Wind, N. et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Hsh3 and Msh6 mismatch-repair protein functions. Nature Genet. 23, 359-362 (1999).
88. Edelmann, W. et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res. 60, 803-807 (2000).
89. Gradia, S., Acharya, S. & Fishel, R. The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell 91, 995-1005 (1997).
90. Gradia, S. et al. hMSH2-hMSH6 forms a hydrolysis independent sliding clamp on mismatched DNA. Mol. Cell 3, 255-261 (1999).
91. Acharya, S., Foster, P. L., Brooks, P. & Fishel, R. The coordinated functions of the E. coli MutS and MutL proteins in mismatch repair. Mol. Cell 12, 233-246 (2003).
92. Geng, H. et al. Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D). J. Biol. Chem. 287, 9777-9791 (2012).
93. Chen, P. C. et al. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res. 65, 8662-8670 (2005).
94. Kadyrov, F. A., Dzantiev, L., Constantin, N. & Modrich, P. Endonucleolytic function of MutLα in human mismatch repair. Cell 126, 297-308 (2006).
95. Pluciennik, A. et al. PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair. Proc. Natl Acad. Sci. USA 107, 16066-16071 (2010).
96. Dzantiev, L. et al. A defined human system that supports bidirectional mismatch-provoked excision. Mol. Cell 15, 31-41 (2004).
97. Holmes, J. J., Clark, S. & Modrich, P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc. Natl Acad. Sci. USA 87, 5837-5841 (1990).
98. Kadyrov, F. et al. A possible mechanism for exonuclease 1-independent eukaryotic mismatch repair. Proc. Natl Acad. Sci. USA 106, 8495-8500 (2009).
99. Hemminki, A. et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nature Genet. 8, 405-410 (1994).
100. Knudson, A. G. Jr Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45, 1437-1443 (1985). This paper is important historically, as it contains Knudson's two-hit hypothesis of carcinogenesis.
101. Fishel, R. & Kolodner, R. D. Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Dev. 5, 382-395 (1995).
102. Loeb, L. A., Springgate, C. F. & Battula, N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 34, 2311-2321 (1974).
103. Markowitz, S. et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995).
104. Markowitz, S. D. & Roberts, A. B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev. 7, 93-102 (1996).
105. Huang, J. et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc. Natl Acad. Sci. USA 93, 9049-9054 (1996).
106. Rampino, N. et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967-969 (1997).
107. Duval, A. & Hamelin, R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 62, 2447-2454 (2002).
108. Mori, Y. et al. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res. 61, 6046-6049 (2001).
109. Percesepe, A. et al. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene 17, 157-163 (1998).
110. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
111. Ricciardone, M. D. et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type I. Cancer Res. 59, 290-293 (1999).
112. Wang, Q. et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 59, 294-297 (1999).
113. Bougeard, G. et al. Diversity of the clinical presentation of the MMR gene biallelic mutations. Fam. Cancer 13, 131-135 (2014).
114. Vasen, H. F. A. et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110, 1020-1027 (1996).
115. Vasen, H. F. A. et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J. Clin. Oncol. 19, 4074-4080 (2001).
116. Peltomäki, P., Gao, X. & Mecklin, J. P. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different versus shared predisposing mutations. Fam. Cancer 1, 9-15 (2001).
117. Mangold, E. et al. A genotype-phenotype correlation in HNPCC: strong predominance of MSH2 mutations in 41 patients with Muir-Torre syndrome. J. Med. Genet. 41, 567-572 (2004).
118. Wagner, A. et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J. Med. Genet. 38, 318-322 (2001).
119. Hendriks, Y. M. C. et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127, 17-25 (2004). This paper details the clinical impact of MSH6 mutations.
120. Wu, Y. et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am. J. Hum. Genet. 65, 1291-1298 (1999).
121. Berends, M. J. W. et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am. J. Hum. Genet. 70, 26-37 (2002).
122. Verma, L. et al. Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J. Med. Genet. 36, 678-682 (1999).
123. Nakagawa, H. et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 64, 4721-4727 (2004).
124. Worthley, D. L. et al. Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 128, 1431-1436 (2005).
125. Hendriks, Y. M. et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 130, 312-322 (2006).
126. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135, 419-428 (2008).
127. Kempers, M. J. E. et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 12, 49-55 (2011).
128. Lynch, H. et al. Lynch syndrome associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am. J. Gastroenterol. 106, 1829-1836 (2011). This paper describes the effect of an EPCAM deletion on two large families, including a family in the United States.
129. Halvarsson, B. et al. Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J. Clin. Pathol. 60, 781-786 (2007).
130. Wimmer, K. & Etzler, J. Constitutional mismatch repairdeficiency syndrome: have we so far seen only the tip of the iceberg? Hum. Genet. 124, 105-122 (2008).
131. Johannesma, P. C. et al. Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations. Clin. Genet. 80, 243-255 (2011).
132. Gylling, A. H. et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 29, 1351-1359 (2008).
133. Hampel, H. et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26, 5783-5788 (2008). This study shows that LS is common enough to justify the genetic testing of all CRCs.
134. Evaluation of Genomic, Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med. 11, 35-41 (2009).
135. Giardiello, F. M. et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis. Colon Rectum 57, 1025-1048 (2014). This is a current and authoritative consensus statement on genetic testing and management of LS.
136. Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087 (2010). This review gives an excellent overview of MSI in CRC.
137. Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808-811 (1997).
138. Veigl, M. L. et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl Acad. Sci. USA 95, 8698-8702 (1998).
139. Cunningham, J. M. et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58, 3455-3460 (1998).
140. Deng, G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10, 191-195 (2004).
141. McGivern, A. et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam. Cancer 3, 101-107 (2004).
142. Domingo, E. et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet. 41, 664-668 (2004).
143. Hegde, M. et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet. Med. 16, 101-116 (2014).
144. Heinen, C. D. & Rasmussen, L. J. Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays. Heredit. Cancer Clin. Practice 10, 9 (2012).
145. Thompson, B. A. et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the insight locusspecific database. Nature Genet. 46, 107-115 (2014). This paper details a scheme for classifying MMR gene variants.
146. Warren, J. J. et al. Structure of the human MutSα DNA lesion recognition complex. Mol. Cell 26, 579-592 (2007).
147. Lerman, C. et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J. Clin. Oncol. 16, 1650-1654 (1998).
148. Eliezer, D., Hadley, D. W. & Koehly, L. M. Exploring psychological responses to genetic testing for Lynch Syndrome within the family context. Psychooncol. 23, 1292-1299 (2014).
149. Aktan-Collan, K. et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: Uptake and long-term satisfaction. Int. J. Cancer (Pred Oncol.) 89, 44-50 (2000).
150. Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nature Med. 12, 1294-1300 (2006).
151. Heinen, C. D. Translating mismatch repair mechanism into cancer care. Curr. Drug Targets 15, 53-64 (2014).
152. Jiricny, J. The multifaceted mismatch-repair system. Nature Rev. Mol. Cell Biol. 7, 335-346 (2006).
153. 6-methylguanine residues in E. coli DNA. Nature 296, 868-869 (1982).
154. Kat, A. et al. An alkylation-tolerant, mutator human cell line is deficient in strand specific mismatch repair. Proc. Natl Acad. Sci. USA 90, 6424-6428 (1993).
155. Stojic, L., Brun, R. & Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair 3, 1091-1101 (2004).
156. Carethers, J. M. et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126, 394-401 (2004). This is an early report on the possible difference in response to 5-fluorouracil based on MSI.
157. Jover, R. et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 45, 365-373 (2009).
158. Sinicrope, F. A. & Sargent, D. J. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin. Cancer Res. 18, 1506-1512 (2012). This paper discusses the clinical implications of MSI, including the possible effect on chemotherapy.
159. Meyers, M. et al. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem. 280, 5516-5526 (2005).
160. Liu, A., Yoshioka, K., Salerno, V. & Hsieh, P. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. Cell Biochem. 105, 245-254 (2008).
161. Kim, J. H. & Kang, G. H. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J. Gastroenterol. 20, 4230-4241 (2014).
162. Bertagnolli, M. M. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group Protocol 89803. J. Clin. Oncol. 27, 1814-1821 (2009).
163. Fallik, D. et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63, 5738-5744 (2003).
164. Braun, M. S. et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26, 2690-2698 (2008).
165. Kim, J. E. et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci. 102, 1706-1711 (2011).
166. Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71, 1836-1848 (2011).
167. Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235-248 (2010).
168. Burn, J. et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 359, 2567-2578 (2008).
169. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-2087 (2011). This study on the efficacy of aspirin for chemoprevention shows the importance of long-term follow-up in such studies.
170. Mcilhatton, M. A. et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev. Res. 4, 684-693 (2011).
171. Laghi, L., Bianchi, P., Roncalli, M. & Malesci, A. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96, 1402-1403 (2004).
172. Järvinen, H. J. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118, 829-834 (2000). This was one of the first, and still one of the best, studies demonstrating the real advantage of colonoscopy screening in LS families.
173. Lynch, H. T., Lynch, P. M. & Harris, R. E. Minimal genetic findings and their cancer control implications: a family with the cancer family syndrome. JAMA 240, 535-538 (1978).
174. Schmeler, K. M. et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354, 261-269 (2006). This study gives strong evidence for the advantage of prophylactic gynaecological surgery among female LS mutation carriers.
175. Ketabi, Z., Gerdes, A.-M., Mosgaard, B., Ladelund, S. & Bernstein, I. The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 133, 526-530 (2014).
176. Church, J. M. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann. Med. 28, 479-482 (1996).
177. Lynch, H. T. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis. Colon Rectum 39, 109-110 (1996).
178. Scaife, C. L. & Rodriguez-Bigas, M. A. Lynch syndrome: implications for the surgeon. Clin. Colorectal Cancer 3, 92-98 (2003).
179. Natarajan, N., Watson, P., Silva-Lopez, E. & Lynch, H. T. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis. Colon Rectum 53, 77-82 (2010). This study gives evidence for the advantage of extended colectomy over more limited surgery in LS patients.
180. Al-Tassan, N., Chmiel, N. H., Maynard, J. & Fleming, N. Inherited variants of MYH associated with somatic G:C→T: A mutations in colorectal tumors. Nature Genet. 30, 227-232 (2002). This is an early report of effects of MYH variants on CRC.
181. Morak, M., Laner, A., Bacher, U., Keiling, C. & Holinski-Feder, E. MUTYH-associated polyposis -variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clin. Genet. 78, 353-363 (2010).
182. Jones, N. et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137, 489-494 (2009).
183. Win, A. K. et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146, 1208-1211 (2014).
184. Morak, M. et al. Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet. 22, 1334-1337 (2014).
185. Lynch, H. T. et al. Attenuated familial adenomatous polyposis (AFAP): a phenotypically and genotypically distinctive variant of FAP. Cancer 76, 2427-2433 (1995). This paper describes attenuated FAP, a syndrome often confused clinically with LS.
186. Lindor, N. M. et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293, 1979-1985 (2005). This was one of the first studies to describe familial CRC type X.
187. Mueller-Koch, Y. et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 54, 1733-1740 (2005).
188. Llor, X. et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin. Cancer Res. 11, 7304-7310 (2005).
189. Valle, L. et al. Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J. Clin. Oncol. 25, 781-786 (2007).
190. Nieminen, T. T. et al. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 141, e23-e26 (2011).
191. Nieminen, T. T. et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology 147, 595-598 (2014).
192. Lindor, N. M. Familial colorectal cancer type X: the other half of hereditary non-polyposis colon cancer syndrome. Surg. Oncol. Clin. N. Am. 18, 637-645 (2009).
193. Lynch, H. T. et al. Communication and technology in genetic counseling for familial cancer. Clin. Genet. 85, 213-222 (2014). This paper discusses the importance of familial communication in hereditary cancer syndrome families and some of the methods currently available to aid this communication.
194. Vasen, H. F. A. et al. The tumor spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int. J. Cancer 46, 31-34 (1990).
195. Drummond, J. T., Li, G.-M., Longley, M. J. & Modrich, P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 268, 1909-1912 (1995).
196. Palombo, F. et al. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268, 1912-1914 (1995).
197. Watson, P. et al. Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast-ovarian cancer. J. Hum. Genet. 40, 591-596 (2003).
198. Peltomäki, P. & Vasen, H. Mutations associated with HNPCC predisposition - update of ICG-HNPCC/INSiGHT mutation database. Dis. Markers 20, 269-276 (2004). This paper lists the mutations found to be associated with LS at the time it was written.
199. Hitchins, M. P. et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 356, 697-705 (2007).
200. Jass, J. R. & Edgar, S. Unicryptal loss of heterozygosity in hereditary non-polyposis colorectal cancer. Pathology 26, 414-417 (1994).
201. Yurgelun, M. B. et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev. Res. 5, 574-582 (2012).
202. Saeterdal, I. et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl Acad. Sci. USA 98, 13255-13260 (2001).